PE20071239A1 - Composiciones que comprenden anticuerpos de dickkopf-1 - Google Patents

Composiciones que comprenden anticuerpos de dickkopf-1

Info

Publication number
PE20071239A1
PE20071239A1 PE2007000031A PE2007000031A PE20071239A1 PE 20071239 A1 PE20071239 A1 PE 20071239A1 PE 2007000031 A PE2007000031 A PE 2007000031A PE 2007000031 A PE2007000031 A PE 2007000031A PE 20071239 A1 PE20071239 A1 PE 20071239A1
Authority
PE
Peru
Prior art keywords
sec
region
group
antibody
nros
Prior art date
Application number
PE2007000031A
Other languages
English (en)
Spanish (es)
Inventor
Janine Shulok
Feng Cong
Mark Fishman
Michael Bardroff
Mariel Donzeau
Seth Ettenberg
Stefanie Urlinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071239A1 publication Critical patent/PE20071239A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
PE2007000031A 2006-01-13 2007-01-12 Composiciones que comprenden anticuerpos de dickkopf-1 PE20071239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75921606P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
PE20071239A1 true PE20071239A1 (es) 2008-02-12

Family

ID=38288117

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001865A PE20120816A1 (es) 2006-01-13 2007-01-12 Composiciones que comprenden anticuerpos de dickkopf-1
PE2007000031A PE20071239A1 (es) 2006-01-13 2007-01-12 Composiciones que comprenden anticuerpos de dickkopf-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001865A PE20120816A1 (es) 2006-01-13 2007-01-12 Composiciones que comprenden anticuerpos de dickkopf-1

Country Status (30)

Country Link
US (3) US8673306B2 (enExample)
EP (1) EP1976594B1 (enExample)
JP (2) JP5552233B2 (enExample)
KR (1) KR101413785B1 (enExample)
CN (1) CN101400406B (enExample)
AR (1) AR060017A1 (enExample)
AU (1) AU2007207787B2 (enExample)
BR (1) BRPI0706524A2 (enExample)
CA (1) CA2636579A1 (enExample)
CR (1) CR10128A (enExample)
CU (1) CU23871B1 (enExample)
EA (1) EA015538B1 (enExample)
EC (1) ECSP088618A (enExample)
GE (1) GEP20125476B (enExample)
HN (1) HN2008001104A (enExample)
IL (1) IL192631A (enExample)
MA (1) MA30158B1 (enExample)
ME (2) ME00010B (enExample)
MY (1) MY153573A (enExample)
NO (1) NO20083477L (enExample)
NZ (1) NZ569555A (enExample)
PE (2) PE20120816A1 (enExample)
SG (1) SG169327A1 (enExample)
SM (1) SMP200800042B (enExample)
SV (1) SV2008002980A (enExample)
TN (1) TNSN08297A1 (enExample)
TW (1) TWI432450B (enExample)
UA (1) UA101944C2 (enExample)
WO (1) WO2007084344A2 (enExample)
ZA (1) ZA200805743B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8450274B2 (en) 2006-05-24 2013-05-28 Theragenetex Co., Ltd. DKK2 protein and use thereof
KR20110117601A (ko) * 2010-04-21 2011-10-27 주식회사 테라젠이텍스 혈관신생과 연관된 화합물을 탐색하는 방법
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
JP5320730B2 (ja) * 2007-12-26 2013-10-23 Ｊｎｃ株式会社 発光基質水溶液およびその製造方法
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2427490A1 (en) * 2009-05-07 2012-03-14 Novartis AG Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
SA110310369B1 (ar) 2009-05-12 2014-09-02 Pfizer أجسام مضادة تخص dkk-1 واستخداماتها
WO2010130832A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2011053665A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
TWI636994B (zh) * 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
WO2012103787A1 (en) * 2011-02-01 2012-08-09 The University Of Hongkong Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
CN103472226A (zh) * 2012-06-08 2013-12-25 上海市肿瘤研究所 血清dkk1在制备早期肝细胞癌或小肝细胞癌的诊断试剂中的用途
CN103487581A (zh) * 2012-06-08 2014-01-01 上海市肿瘤研究所 血清dkk1在制备甲胎蛋白阴性肝细胞癌的诊断试剂中的用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9359444B2 (en) * 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
CN103083686B (zh) * 2013-02-18 2014-09-10 上海交通大学医学院附属仁济医院 Dkk4基因及其编码蛋白在制备药物中的应用
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
US10398765B2 (en) 2014-07-03 2019-09-03 Yale University Dickkopf2 (Dkk2) inhibition suppresses tumor formation
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
DE102016206820B4 (de) 2015-04-22 2017-07-27 BSH Hausgeräte GmbH Weiterentwicklung eines Induktionswasserkochers, einer Kaffeemaschine und einer Suppenmaschine
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN105203773A (zh) * 2015-09-28 2015-12-30 成都博奥新景医学科技有限公司 一种人Dickkopf-1蛋白（DKK-1）定量检测试剂盒
EP3368567B1 (en) * 2015-10-28 2025-10-01 Yale University Humanized anti-dkk2 antibody and uses thereof
RU2656160C2 (ru) 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
JP7374765B2 (ja) * 2016-10-26 2023-11-07 リープ セラピューティクス，インコーポレイテッド 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用
CN110799212A (zh) * 2017-05-10 2020-02-14 古德T细胞有限公司 特异性存在于调节性t细胞中的dkk1蛋白及其用途
KR102370637B1 (ko) * 2019-01-15 2022-03-07 (주)바이오니아 Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물
CN113747917B (zh) * 2019-02-01 2024-11-29 得克萨斯州大学系统董事会 针对MHC结合的人Dickkopf-1肽的单克隆抗体及其应用
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CN112180094A (zh) * 2019-07-04 2021-01-05 上海东慈生物科技有限公司 Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
US20250270304A1 (en) * 2020-12-23 2025-08-28 Phenomic Ai Anti-activin antibodies and methods of using the same
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN117916377A (zh) * 2021-09-26 2024-04-19 安沛治疗有限公司 针对dkk1的适体及其用途
CN116514966A (zh) * 2022-01-28 2023-08-01 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
WO2024216064A1 (en) * 2023-04-14 2024-10-17 Twist Bioscience Corporation Compositions and methods related to dkk1 binders
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
ATE505543T1 (de) 1997-04-16 2011-04-15 Millennium Pharm Inc Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AU5233599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
US7041805B2 (en) * 1998-09-01 2006-05-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
MXPA03007327A (es) * 2001-02-16 2005-02-14 Genentech Inc Tratamiento que involucra la proteina dickkopf-1 o antagonistas de la misma.
EP1381631B1 (en) * 2001-04-24 2010-10-13 Bayer Corporation Human anti timp-1 antibodies
WO2003053215A2 (en) 2001-11-07 2003-07-03 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
ES2362681T3 (es) 2002-12-05 2011-07-11 The Board Of Trustees Of The University Of Arkansas Determinantes moleculares de la osteopatía por mieloma y uso de los mismos.
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
ES2402576T3 (es) * 2005-11-14 2013-05-06 Bioren, Inc. Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas

Also Published As

Publication number Publication date
CU20080133A7 (es) 2012-06-21
US8673306B2 (en) 2014-03-18
JP5552233B2 (ja) 2014-07-16
MA30158B1 (fr) 2009-01-02
EA015538B1 (ru) 2011-08-30
IL192631A0 (en) 2011-08-01
NO20083477L (no) 2008-10-13
PE20120816A1 (es) 2012-08-01
AU2007207787A1 (en) 2007-07-26
SMP200800042B (it) 2009-07-14
GEP20125476B (en) 2012-04-25
ME00010B (me) 2010-06-10
EP1976594B1 (en) 2015-05-06
AR060017A1 (es) 2008-05-21
CN101400406A (zh) 2009-04-01
US9296813B2 (en) 2016-03-29
KR101413785B1 (ko) 2014-07-09
TNSN08297A1 (en) 2009-12-29
US20140170147A1 (en) 2014-06-19
ZA200805743B (en) 2009-08-26
TW200804417A (en) 2008-01-16
US20140341901A1 (en) 2014-11-20
ECSP088618A (es) 2008-08-29
HK1121420A1 (en) 2009-04-24
SG169327A1 (en) 2011-03-30
EP1976594A2 (en) 2008-10-08
WO2007084344A3 (en) 2008-02-14
JP2013099334A (ja) 2013-05-23
IL192631A (en) 2015-06-30
MY153573A (en) 2015-02-27
CR10128A (es) 2008-08-25
US20120023600A1 (en) 2012-01-26
BRPI0706524A2 (pt) 2011-03-29
SV2008002980A (es) 2010-05-21
WO2007084344A2 (en) 2007-07-26
EA200801679A1 (ru) 2009-02-27
HN2008001104A (es) 2011-06-08
MEP1308A (xx) 2010-02-10
JP2009523421A (ja) 2009-06-25
KR20080085908A (ko) 2008-09-24
TWI432450B (zh) 2014-04-01
CU23871B1 (es) 2013-03-27
CN101400406B (zh) 2014-01-29
SMAP200800042A (it) 2008-07-30
NZ569555A (en) 2011-12-22
CA2636579A1 (en) 2007-07-26
UA101944C2 (ru) 2013-05-27
AU2007207787B2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
PE20071239A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
EA202191432A1 (ru) Агонисты glp-1r и их применения
SA521430550B1 (ar) Glp-1r عوامل مساعدة لـ واستخداماتها
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
DK1385864T3 (da) Anti-VEGF-2-antistoffer
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
IL168058A (en) Antibody preferentially linked to cell Ca125 / 0722p relative to ca125 / 0722p deciduous cell, the pharmaceutical composition containing it and its use in the preparation of a drug
PE20050339A1 (es) Anticuerpos humanos modificados anti-igf-1r
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
MX2023010764A (es) Anticuerpo anti componente del complemento 1s (c1s).
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Legal Events

Date Code Title Description
FC Refusal